Generic molecule: linaclotide
Company: Ironwood Pharmaceuticals
Approval date: Aug. 30
The scoop: The approval of partner Ironwood's linaclotide in late August is one of many reasons Forest Labs has been oft-cited as a takeover target in biopharma. Forest markets the drug, which is OK'd for chronic idiopathic constipation and to treat irritable bowel syndrome with constipation. Morgan Stanley has estimated potential peak sales at $2 billion.